Edwards Lifesciences Corporation (EW), headquartered in Irvine, California, is a global medical technology company specializing in structural heart disease treatments, with a market capitalization of approximately $49.1 billion. The company develops innovative products, including heart valves and related technologies, partnering with physicians to improve cardiovascular health, extend patients’ lives, and enhance their overall quality of life.
EW is set to report its Q3 2026 earnings after the market closes on Wednesday, November 4, 2026. Ahead of the release, analysts expect diluted EPS of 73 cents, up 9% from 67 cents in the year-ago quarter. Likewise, EW has exceeded Wall Street’s EPS estimates in three of the past four quarters.